Real-World Data on the Effectiveness of Ustekinumab and Risankizumab for Crohn's Disease.

Q2 Medicine

Inflammatory Intestinal Diseases Pub Date : 2025-08-18 eCollection Date: 2025-01-01 DOI:10.1159/000547048

Ryo Morikawa, Toshimitsu Fujii, Akiko Tamura, Ami Kawamoto, Shuji Hibiya, Kento Takenaka, Hiromichi Shimizu, Kazuo Ohtsuka, Ryuichi Okamoto

{"title":"Real-World Data on the Effectiveness of Ustekinumab and Risankizumab for Crohn's Disease.","authors":"Ryo Morikawa, Toshimitsu Fujii, Akiko Tamura, Ami Kawamoto, Shuji Hibiya, Kento Takenaka, Hiromichi Shimizu, Kazuo Ohtsuka, Ryuichi Okamoto","doi":"10.1159/000547048","DOIUrl":null,"url":null,"abstract":"Introduction: No real-world studies have compared efficacy of ustekinumab (UST) and risankizumab (RZB) for the treatment of Crohn's disease (CD).Methods: We retrospectively collected the data of patients with CD treated with UST or RZB between May 2017 and March 2024 at the Institute of Science Tokyo and analyzed clinical remission rate at weeks 8 and 28 using Harvey-Bradshaw Index (HBI), with remission defined as a HBI ≤4.Result: A total of 111 patients who were treated with UST and 29 patients treated with RZB were included in the analysis. RZB had higher efficacy both at weeks 8 (82.8% vs. 62.2%, p = 0.0465) and 28 (79.3% vs. 56.8%, p = 0.0321) than UST in the full study cohort, and at weeks 8 (55.6% vs. 18.4%, p = 0.0352) and 28 (66.7% vs. 18.4%, p = 0.0083) in the patients with clinically active disease and anti-TNFα exposed patients. During the observation period, 1 patient with RZB (3.45%) experienced an adverse event that required hospitalization, and 1 patient in the UST group (0.900%) experienced an adverse event that led to treatment discontinuation.Conclusion: RZB may offer greater short-term efficacy than UST, with an acceptable safety profile in real-world settings.","PeriodicalId":13605,"journal":{"name":"Inflammatory Intestinal Diseases","volume":"10 1","pages":"285-289"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503637/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammatory Intestinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000547048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: No real-world studies have compared efficacy of ustekinumab (UST) and risankizumab (RZB) for the treatment of Crohn's disease (CD).

Methods: We retrospectively collected the data of patients with CD treated with UST or RZB between May 2017 and March 2024 at the Institute of Science Tokyo and analyzed clinical remission rate at weeks 8 and 28 using Harvey-Bradshaw Index (HBI), with remission defined as a HBI ≤4.

Result: A total of 111 patients who were treated with UST and 29 patients treated with RZB were included in the analysis. RZB had higher efficacy both at weeks 8 (82.8% vs. 62.2%, p = 0.0465) and 28 (79.3% vs. 56.8%, p = 0.0321) than UST in the full study cohort, and at weeks 8 (55.6% vs. 18.4%, p = 0.0352) and 28 (66.7% vs. 18.4%, p = 0.0083) in the patients with clinically active disease and anti-TNFα exposed patients. During the observation period, 1 patient with RZB (3.45%) experienced an adverse event that required hospitalization, and 1 patient in the UST group (0.900%) experienced an adverse event that led to treatment discontinuation.

Conclusion: RZB may offer greater short-term efficacy than UST, with an acceptable safety profile in real-world settings.

Abstract Image

查看原文本刊更多论文

Ustekinumab和Risankizumab治疗克罗恩病有效性的真实世界数据

没有现实世界的研究比较ustekinumab （UST）和risankizumab （RZB）治疗克罗恩病（CD）的疗效。方法：回顾性收集2017年5月至2024年3月在东京科学研究所接受UST或RZB治疗的CD患者的数据，并使用Harvey-Bradshaw指数（HBI）分析第8周和第28周的临床缓解率，缓解定义为HBI≤4。结果：共纳入111例UST患者和29例RZB患者。在整个研究队列中，RZB在第8周（82.8% vs. 62.2%, p = 0.0465）和28周（79.3% vs. 56.8%, p = 0.0321）的疗效均高于UST，在临床活动性疾病和抗tnf α暴露患者中，RZB在第8周（55.6% vs. 18.4%, p = 0.0352）和28周（66.7% vs. 18.4%, p = 0.0083）的疗效高于UST。观察期间，1例RZB患者（3.45%）发生不良事件需要住院治疗，1例UST组患者（0.900%）发生不良事件导致停药。结论：RZB可能比UST具有更大的短期疗效，在现实环境中具有可接受的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊